Invicro’s clinical imaging capabilities span from early phase first-in-human through late phase and post-approval studies. We focus on studies containing imaging-based endpoints requiring robust, independent assessments to ascertain drug efficacy. For more details on our early phase capabilities please click here.

Contact us


Invicro’s late phase imaging solutions focuses on therapeutic areas most associated with imaging-based endpoints including oncology, neurology (CNS), cardiovascular, musculoskeletal and gastrointestinal. Our experience comes from years of successful execution of Phase II-IV studies across the development spectrum led by a leadership team with an average of 25 years of industry experience.

In the Oncology space, we have read studies using establish criteria, including RECIST, CHESON, RANO, LUGANO, PCWG, and IMWG, as well as those modified for immuno-oncology, such as iRECIST, irRECIST, LYRIC and irRC. Our independent readers are leaders in their clinical fields and hail from clinics and universities worldwide.

In the CNS space, we have performed internal analysis and independent reads used established criteria and advanced image analysis including validated pipelines for SUVr, Centiloids, tracer kinetic modeling, perfusion analysis, synaptic density imaging and novel analysis such as AmyloidIQ and TauIQ.


Invicro’s imaging core lab is supported by a state-of-the-art image management platform iPACS.  Utilizing a modality agnostic workflow to intake imaging data we can QC, analyze and read a variety of imaging modalities, including:

  • CT
  • MRI
  • PET
  • NM bone scan
  • Echo
  • X-ray
  • Photography
  • Ultrasound

Our team of scientists are also actively engaged in trials with novel modalities and techniques such as resting-state fMRI, phMRI, MRS, DCE-MRI, ALS and Dynamic X-Ray.

Advanced Image Analysis

Our imaging core lab is supported by Invicro’s advanced image analysis team of fifty scientists, including twenty-five PhDs. We specialize in various advanced image analysis workflows, including:

  • Volumetrics
  • Tumor quantification
  • Tracer kinetic analysis
  • Amyloid load
  • Dosimetry
  • Antigen density quantification
  • PK-PD analysis
  • Vessel characterization,
  • Cardiac function
  • Functional MRI
  • Multi-atlas segmentation

Learn More